Biotech

All Articles

Regeneron's Opdualag opponent shows 57% feedback fee

.Regeneron is back along with lasting follow-up for its LAG-3 prevention and PD-1 inhibitor combo in...

AstraZeneca articles data on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has shared a very early consider the functionality of its own internal antibody-drug co...

iTeos- GSK's TIGIT celebrity presents meaningful enhancement

.After revealing a period 3 launch based upon favorable midstage end results, iTeos and GSK are even...

More joint FDA can easily increase rare disease R&ampD: record

.The FDA must be much more available as well as collaborative to let loose a rise in approvals of ra...

Zenas, MBX, Bicara scalp to Nasdaq in warm day for biotech IPOs

.It is actually an uncommonly active Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara R...

Atea's COVID antiviral falls short to stop hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has stopped working another COVID-19 test, yet the biotech still ke...

Neurocrine's quote to spare mental illness possibility falls short

.Neurocrine Biosciences' mental illness plan pivot has neglected. The biotech was actually not able ...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has made a late entrance to the radioligand gathering, spending 100 thousand europeans ($ 11...

F 2G rears $100M for 2nd effort to get new antifungal to market

.After F2G's 1st try to get a new course of antifungal to market was wrecked by the FDA, the U.K.-ba...

Moderna targets $1.1 B in R&ampD costs cuts, drops 5 programs amidst success stress

.Moderna has vowed to reduce R&ampD costs through $1.1 billion through 2027. The choice to retract t...